Home Newsfeeds Deutsche Bank Maintains Hold on Campbell Soup, Lowers Price Target to $53

Deutsche Bank Maintains Hold on Campbell Soup, Lowers Price Target to $53

Deutsche Bank analyst Steve Powers maintains Campbell Soup (NYSE:CPB) with a Hold and lowers the price target from $54 to $53.

byBenzinga Newsdesk

March 20, 2023

1 minute read

Deutsche Bank analyst Steve Powers maintains Campbell Soup (NYSE:CPB) with a Hold and lowers the price target from $54 to $53.

FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients

By Nicolas Jose Rodriguez

November 12, 10:09 PM

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment.

SPRC

Analyst Ratings

The Latest Analyst Ratings for Lowe’s Companies

By Benzinga Insights

March 2, 4:00 PM

Within the last quarter, Lowe’s Companies (NYSE:LOW) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

LOW

Bitcoin Expected To Plummet Further To $38K, According to 10X Research

By Mehab Qureshi

January 15, 4:11 AM

Bitcoin (CRYPTO: BTC) may potentially witness a drop to the $38,000 level, as per the prediction by 10x Research. The cryptocurrency is currently experiencing a pullback after the official launch of spot ETFs in the United States.

BTC

LianBio Announces China National Medical Products Administration Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy

By Happy Mohamed

April 21, 8:06 AM

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China's National Medical Products Administration

LIAN

Deutsche Bank Maintains Hold on Campbell Soup, Lowers Price Target to $53

Related Posts

FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients

The Latest Analyst Ratings for Lowe’s Companies

Bitcoin Expected To Plummet Further To $38K, According to 10X Research

LianBio Announces China National Medical Products Administration Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy